Novo Nordisk's November Gauntlet: A Courtroom Setback, Lilly's Raised Bar and the CagriSema Caveat
Published on 11/02/2026 at 21:11 | Editorial boerse-global.de
Novo Nordisk heads into a crowded November with its competitive narrative under scrutiny on three separate fronts: a legal bid that fell short, a rival's upgraded outlook and a pipeline whose data still needs to prove itself commercially.
A US district judge, Zahid Quraishi, declined on 26 October to grant a preliminary injunction against Eli Lilly & Company and Lilly USA, LLC. The ruling lets Lilly keep running the weight-loss advertising Novo had challenged while the case proceeds. It does not end Novo's lawsuit, and it says nothing about whether the claims of misleading promotion will ultimately hold up. Nor does it amount to judicial endorsement of the contested ads. For investors, the takeaway is narrower than a defeat: Novo missed the temporary ad freeze it sought, and the underlying dispute remains live.
The setback lands as Lilly applies pressure well beyond the courtroom. Reuters reported on Wednesday that Lilly's Phase 3 results for retatrutide, pitted against Novo's Ozempic, showed greater weight loss and a sharper reduction in blood sugar among adults with type 2 diabetes. The readout weighed on sentiment toward Novo. Clinical comparisons and advertising litigation are distinct matters — one describes treatment outcomes, the other targets specific promotional claims — so the injunction outcome carries no verdict on the science.
A Raised Forecast, and a Split Earnings Picture
On Thursday, Lilly lifted its 2026 revenue guidance to $91–92 billion, citing demand for its injectable weight-loss drugs. Reuters framed the move as a widening of Lilly's lead over Novo. The bar is now set by a competitor that is not only advancing its pipeline but already raising business expectations, which makes positive study data from Novo's own portfolio necessary but not sufficient — such results are not yet evidence of matching sales.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The guidance revision was not uniformly upbeat. Lilly trimmed its adjusted profit outlook on transaction-related charges, so revenue growth and earnings moved in opposite directions in the same update.
Novo's scientific counterpoint came roughly two weeks ago, with post-hoc analyses from the REDEFINE 1 trial. Among women overall, the investigational drug CagriSema was associated with an average weight loss of 25.0% after 68 weeks. Novo explicitly labelled the analyses as retrospective, and CagriSema remains investigational — the findings hint at development potential without constituting approval or proof of future commercial success.
Further visibility is scheduled. Contributions on semaglutide and the investigational Efruxifermin are lined up for The Liver Meeting from 5 to 9 November, with obesity-portfolio data to follow at ObesityWeek from 14 to 17 November.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Before any of that, Novo will release results for the first nine months on 4 November — the next financial test and the company's own reference point against which the Lilly news will be measured. The distinction that matters for investors is the one between scientific promise and commercial delivery: Lilly has already raised its revenue expectations, while Novo's pipeline progress has yet to translate into sales.
Ad
Novo Nordisk Stock: New Analysis - 2 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
